<DOC>
	<DOCNO>NCT00525798</DOCNO>
	<brief_summary>The purpose Phase III study evaluate efficacy safety oral salmon calcitonin treatment patient osteoporosis</brief_summary>
	<brief_title>A Study Evaluate Oral Salmon Calcitonin Treatment Osteoporosis Postmenopausal Women Taking Calcium Vitamin D</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Postmenopausal woman osteoporosis , ambulatory , general good health , receive medication affect bone metabolism , free underlie condition , osteoporosis , may result abnormal bone metabolism . BMD Tscore 4.0 ( base absolute value g/cm2 give protocol ) one measure sit More 2 prevalent vertebral fracture ( Genant et al , 15 ) . If BMD low 2.5 Tscore one measure site , participant exclude study , severe vertebral fracture ( Genant et al , 15 ) . Evidence clinical osteoporotic fracture and/or history clinical osteoporotic fracture ( exclude wrist fracture ) BMD Tscore &gt; 1.5 follow region : Lumbar spine , femoral neck total hip . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Osteoporosis , oral salmon calcitonin , treatment , efficacy , tolerability</keyword>
</DOC>